anti-CDKN2B (CDKN2B) Antikörper

anti-Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) Antikörper (CDKN2B)
Auf finden Sie aktuell 140 Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B) Antikörper von 20 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen CDKN2B Proteine (7) und CDKN2B Kits (2) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 159 CDKN2B Produkte verfügbar.
AV083695, CDK4I, cdk4l, CDKN2A, INK4b, MTS2, p14-INK4b, P15, p15(INK4b), p15INK4b, TP15

Meistgesuchte Reaktivitäten zu anti-CDKN2B (CDKN2B) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Human CDKN2B Antikörper:

anti-Mouse (Murine) CDKN2B Antikörper:

anti-Rat (Rattus) CDKN2B Antikörper:

Alle verfügbaren anti-CDKN2B Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Am meisten referenzierte anti-CDKN2B Antikörper

  1. Mouse (Murine) Polyclonal CDKN2B Primary Antibody für IF - ABIN181357 : Franklin, Xiong: Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. in Molecular biology of the cell 1997 (PubMed)

  2. Dog (Canine) Polyclonal CDKN2B Primary Antibody für WB - ABIN2774603 : Scott, Kimura, Dong, Ichinohasama, Bergen, Kerviche, Sheridan, DeCoteau: Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia. in Leukemia research 2004 (PubMed)

  3. Human Polyclonal CDKN2B Primary Antibody für ELISA, WB - ABIN4342269 : Geyer: Strategies to re-express epigenetically silenced p15(INK4b) and p21(WAF1) genes in acute myeloid leukemia. in Epigenetics 2010 (PubMed)

  4. Human Monoclonal CDKN2B Primary Antibody für IF, IP - ABIN1449282 : Hannon, Beach: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. in Nature 1994 (PubMed)

  5. Human Polyclonal CDKN2B Primary Antibody für ICC, IF - ABIN407770 : Siddiqi, Terry, Matushansky: Hiwi mediated tumorigenesis is associated with DNA hypermethylation. in PLoS ONE 2012 (PubMed)

Weitere Antikörper gegen CDKN2B Interaktionspartner

Human Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B) Interaktionspartner

  1. These data support the hypothesis that decreased p15 expression is a robust biomarker for distinguishing nevus from melanoma.

  2. Here we present, as far as we are aware, the first case of metastatic microcystic adnexal carcinoma with DNA sequencing results indicating a mutation in TP53 (zeige TP53 Antikörper) and chromosomal losses in cyclin dependent kinase inhibitor 2A (CDKN2A (zeige CDKN2A Antikörper)) and cyclin dependent kinase inhibitor 2B (CDKN2B).

  3. results provide evidence for the influence of genetic variants at CDKN2A (zeige CDKN2A Antikörper)/B locus with the risk of developing B-AL

  4. Case Report: knee joint malignant tenosynovial giant cell tumor with CDKN2A (zeige CDKN2A Antikörper)/B genomic alteration.

  5. Total 1208 differentially expressed genes were screened, and 5 coronary artery disease (CAD (zeige CAD Antikörper))-associated miRNAs (including miR (zeige MLXIP Antikörper)-92a) were predicted associated with CAD (zeige CAD Antikörper). The SVM classifier was constructed based on the 41 featured genes and had high recognition efficiency. Only one lncRNA CDKN2B-antisense targeting miR (zeige MLXIP Antikörper)-92a was obtained.

  6. In a suspicious INK4b-ARF-INK4a (zeige CDKN2A Antikörper) gene cluster at chromosome 9p21 in uveal melanoma cells, aberrant INK4a (zeige CDKN2A Antikörper) and INK4b defects were simultaneously endogenously auto-corrected after targeting the suppression of abnormal ANRIL lncRNA.

  7. Upregulation of ZEB1-AS1 colorectal cancer promotes cell proliferation and inhibits cell apoptosis. In addition, cell cycle inhibitory protein p15 participates in the oncogenic function of ZEB1-AS1. Collectively, ZEB1-AS1 has asignificant effect on colorectal cancer pathological process and serves as a valuable prognostic biomarker for colorectal cancer.

  8. Genetic association analyses using the cpRNFLT with 768 points suggest that the CDKN2B gene was associated with paracentral/lower hemifield scotomas.

  9. We found that CDKN2B was a virtual target of miR (zeige MLXIP Antikörper)-15a-5p with potential binding sites in the 3'UTR (zeige UTS2R Antikörper) of CDKN2B (77-83 bp). We also showed that miR (zeige MLXIP Antikörper)-15a-5p could bind to the CDKN2B 3'UTR (zeige UTS2R Antikörper). The data revealed a negative regulatory role of miR (zeige MLXIP Antikörper)-15a-5p in the apoptosis of smooth muscle cells via targeting CDKN2B, and showed that miR (zeige MLXIP Antikörper)-15a-5p could be a novel therapeutic target of AAA (zeige APP Antikörper).

  10. Meta-analysis indicates that CDKN2B gene rs1063192 polymorphism is significantly associated with a decreased risk of glaucoma. [meta-analysis]

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B) Interaktionspartner

  1. Data show that the Wnt (zeige WNT2 Antikörper)-effector hepatocyte nuclear factor 1-alpha (Tcf1 (zeige HNF1A Antikörper)) is recruited to and triggers transcription of the Ink4/Arf (zeige CDKN2A Antikörper) tumor suppressor locus, such as as p15Ink4b, p16Ink4a (zeige CDKN2A Antikörper) and p19Arf (zeige CDKN2A Antikörper).

  2. Loss of Nf2 (zeige NF2 Antikörper) and Cdkn2a (zeige CDKN2A Antikörper)/b have synergistic effects with PDGF-B (zeige PDGFB Antikörper) overexpression promoting meningioma malignant transformation.

  3. Loss of CDKN2B may not only promote cardiovascular disease through the development of atherosclerosis but may also impair TGFbeta (zeige TGFB1 Antikörper) signaling and hypoxic neovessel maturation.

  4. Control of CD8 (zeige CD8A Antikörper) T cell proliferation and terminal differentiation by active STAT5 (zeige STAT5A Antikörper) and CDKN2A/CDKN2B.

  5. Radiation-induced double strand breaks cooperate with loss of Ink4 (zeige CDKN2A Antikörper) and Arf (zeige CDKN2A Antikörper) tumor suppressors to generate high-grade gliomas that are commonly driven by Met amplification and activation.

  6. When overexpressed in naked mole rat or human cells, pALT(INK4a (zeige CDKN2A Antikörper)/b) has stronger ability to induce cell-cycle arrest than either p15(INK4b) or p16(INK4a (zeige CDKN2A Antikörper)).

  7. Cdk4 (zeige CDK4 Antikörper) and Cdk6 (zeige CDK6 Antikörper) cooperate in hematopoietic tumor development and suggest a role for Cdk6 (zeige CDK6 Antikörper) in sequestering INK4 (zeige CDKN2A Antikörper) proteins away from Cdk4 (zeige CDK4 Antikörper).

  8. Data indicate that loss of cyclin-dependent kinase inhibitor p15 (p15Ink4b) collaborates with oncogene (zeige RAB1A Antikörper) fusion protein Nup98 (zeige NUP98 Antikörper)-HoxD13 (zeige HOXD13 Antikörper) transgene in the development of predominantly myeloid neoplasms.

  9. Loss of CDKN2B promotes atherosclerosis by increasing the size and complexity of the lipid-laden necrotic core through impaired efferocytosis.

  10. Meningioma progression in mice triggered by Nf2 (zeige NF2 Antikörper) and Cdkn2ab inactivation.

CDKN2B Antigen-Profil

Beschreibung des Gens

This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported.

Alternative names and synonyms associated with CDKN2B

  • cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (CDKN2B) Antikörper
  • Cyclin-dependent kinase 4 inhibitor B (cdn2b) Antikörper
  • cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (cdkn2b) Antikörper
  • cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (Cdkn2b) Antikörper
  • AV083695 Antikörper
  • CDK4I Antikörper
  • cdk4l Antikörper
  • CDKN2A Antikörper
  • INK4b Antikörper
  • MTS2 Antikörper
  • p14-INK4b Antikörper
  • P15 Antikörper
  • p15(INK4b) Antikörper
  • p15INK4b Antikörper
  • TP15 Antikörper

Bezeichner auf Proteinebene für CDKN2B

Cyclin-dependent kinase 4 inhibitor B , CDK inhibitory protein , CDK4B inhibitor , MTS-2 , cyclin-dependent kinase 4 inhibitor B , cyclin-dependent kinases 4 and 6 binding protein , multiple tumor suppressor 2 , p14-INK4b , p14_CDK inhibitor , p14_INK4B , p15 CDK inhibitor , p15-INK4b , p15_INK4B , cyclin-dependent kinase inhibitor p15 , cyclin-dependent kinase inhibitor p15INK4b , cyclin-dependent kinase inhibitor protein , Cyclin dependent kinase inhibitor 2B (p15, inhibits CDK4) , cyclin dependant kinase inhibitor , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2B , cyclin-dependent kinase inhibitor 2B (melanoma, p16, inhibits CDK4) , p15INK4b tumor suppressor

709209 Macaca mulatta
100196147 Salmo salar
448767 Xenopus (Silurana) tropicalis
779240 Xenopus laevis
1030 Homo sapiens
12579 Mus musculus
25164 Rattus norvegicus
481563 Canis lupus familiaris
397227 Sus scrofa
527124 Bos taurus
395076 Gallus gallus
Ausgewählte Anbieter für anti-CDKN2B (CDKN2B) Antikörper
Haben Sie etwas anderes gesucht?